基于配体的 CAR 设计增强胶质母细胞瘤中靶向 CD70 的 CAR-T 细胞持久性

Ligand-based CAR design enhances durability of CD70-targeted CAR T cells in glioblastoma.

用于胶质母细胞瘤治疗的 CD70 靶向 CAR-T 细胞比较分析显示配体基构建体疗效更优

A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.

通用靶向 mSA2 CAR-T 细胞用于胶质母细胞瘤治疗

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma.

通过体外转导经 TS-2021 增强的 CD70 CAR-T 细胞显示出针对胶质母细胞瘤的强效抗肿瘤疗效

CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma.

通过将携带 IL15 的 OAd 整合到 CAR-T 细胞中，我们展示了一种协同策略，可同时增强病毒溶瘤作用、维持 T 细胞持久性并对抗 GBM 免疫抑制。

生物偶联的类液体固体增强实体瘤-CAR-T 细胞相互作用的表征

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.

三维生物偶联类液体固体 (LLS) 增强实体瘤-CAR-T 细胞相互作用的表征

Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions.

靶向胶质母细胞瘤的嵌合抗原受体：现状与未来展望

Current and future perspectives of chimeric antigen receptors against glioblastoma.

oHSV-1 感染的胶质母细胞瘤释放的 IFN-γ 增强 CD70 特异性 CAR-T 治疗

Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.

CD70 作为复发性胶质母细胞瘤及其微环境中可干预的免疫治疗靶点

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.

CD70 在复发性 GBM 细胞的侵袭性和维持中发挥关键作用。